CPRX common stock is now effectively worthless as a public security — the delisting and deregistration sequence means no exchange trading and no SEC reporting. Existing shareholders should expect the stock to trade only on the OTC markets with minimal liquidity and zero regulatory oversight. The single holder of record suggests a buyout or going-private transaction may have already occurred or is imminent; monitor for a subsequent merger or tender offer filing.
Price Chart
Executive Summary
Catalyst Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective July 24, 2026, reporting only one holder of record. This follows a Nasdaq-initiated delisting via Form 25-NSE filed nine days earlier, completing the company's exit from public markets and ending all SEC reporting obligations.
Key Facts
- Catalyst Pharmaceuticals filed Form 15-12G to terminate registration under Section 12(g) of the Securities Exchange Act of 1934.
- The filing reports approximately one (1) holder of record as of the certification date.
- The filing was made effective on July 24, 2026, the same day it was filed.
- This follows a Nasdaq-initiated delisting via Form 25-NSE filed on July 15, 2026, which was a mandatory removal under Rule 12d2-2(a)(3).
- The company will cease all SEC reporting obligations under Sections 13 and 15(d) of the Exchange Act.
Financial Impact
Complete loss of public market transparency and liquidity for a $3.9B market-cap company; shareholders will be forced to hold unregistered stock with no SEC reporting.
Risk Factors
- Complete loss of public market liquidity; shares may become untradeable or trade at a deep discount on the OTC markets.
- No further SEC filings means zero transparency on financials, operations, or material events.
- The single holder of record suggests a potential squeeze-out or going-private transaction at an unfavorable price for minority shareholders.
- Potential for shareholder litigation if the delisting/deregistration was not accompanied by a fair going-private process.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 15-12G Filing (CPRX) — Batch item 1 | 0001193125-26-315836 |
| Document: 0001193125-26-315836-index-headers.html | 0001193125-26-315836 |
| Document: 0001193125-26-315836-index.html | 0001193125-26-315836 |
| Document: 0001193125-26-315836.txt | 0001193125-26-315836 |
| 15-12G Filing (CPRX) — Batch item 5 | 0001193125-26-315836 |
| Document: 0001193125-26-315836-index-headers.html | 0001193125-26-315836 |
| Document: 0001193125-26-315836-index.html | 0001193125-26-315836 |
| Document: 0001193125-26-315836.txt | 0001193125-26-315836 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 22, 2026 5w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 24, 2026 9w ago | 15-12G | $31.49 awaiting T+5 | awaiting T+5 | — | — |
Jul 17, 2026 11w ago | EFFECT | $31.49 $31.49 | · 0.00% | ▼ −0.59% | — |
Jul 15, 2026 11w ago | 25-NSE | $31.49 $31.49 | · 0.00% | ▼ −0.98% | — |
Jul 8, 2026 12w ago | 8-K | $31.47 $31.49 | ▲ +0.06% | ▲ +0.20% | — |
Jun 30, 2026 13w ago | DEFA14A | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
Jun 30, 2026 13w ago | 8-K | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
May 28, 2026 18w ago | PREM14A | $31.23 $31.28 | ▲ +0.16% | ▲ +0.45% | — |
May 12, 2026 20w ago | DEFA14A | $31.14 $31.23 | ▲ +0.29% | ▲ +0.21% | — |
May 11, 2026 20w ago | Press Release | $31.14 $31.23 | ▼ −0.29% | ▼ −0.21% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access